Loading...

AxoGen

Nasdaq:AXGN
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AXGN
Nasdaq
$761M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
  • AxoGen has significant price volatility in the past 3 months.
AXGN Share Price and Events
7 Day Returns
-5.1%
NasdaqCM:AXGN
0.6%
US Medical Equipment
-0.3%
US Market
1 Year Returns
-64.7%
NasdaqCM:AXGN
15.8%
US Medical Equipment
3.9%
US Market
AXGN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AxoGen (AXGN) -5.1% -1.8% -6.9% -64.7% 193.6% 695.5%
US Medical Equipment 0.6% 3.2% 14.3% 15.8% 64.2% 105%
US Market -0.3% 2.3% 2.3% 3.9% 36.7% 41.8%
1 Year Return vs Industry and Market
  • AXGN underperformed the Medical Equipment industry which returned 15.8% over the past year.
  • AXGN underperformed the Market in United States of America which returned 3.9% over the past year.
Price Volatility
AXGN
Industry
5yr Volatility vs Market

Value

 Is AxoGen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AxoGen. This is due to cash flow or dividend data being unavailable. The share price is $19.41.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AxoGen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AxoGen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:AXGN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.69
NasdaqCM:AXGN Share Price ** NasdaqCM (2019-07-19) in USD $19.41
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.15x
United States of America Market PE Ratio Median Figure of 3,083 Publicly-Listed Companies 17.92x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AxoGen.

NasdaqCM:AXGN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AXGN Share Price ÷ EPS (both in USD)

= 19.41 ÷ -0.69

-28.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AxoGen is loss making, we can't compare its value to the US Medical Equipment industry average.
  • AxoGen is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does AxoGen's expected growth come at a high price?
Raw Data
NasdaqCM:AXGN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -28.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
59%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.38x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AxoGen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AxoGen's assets?
Raw Data
NasdaqCM:AXGN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $3.60
NasdaqCM:AXGN Share Price * NasdaqCM (2019-07-19) in USD $19.41
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.43x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.8x
NasdaqCM:AXGN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AXGN Share Price ÷ Book Value per Share (both in USD)

= 19.41 ÷ 3.60

5.4x

* Primary Listing of AxoGen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AxoGen is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess AxoGen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. AxoGen has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is AxoGen expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
59%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AxoGen expected to grow at an attractive rate?
  • AxoGen's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • AxoGen's earnings growth is expected to exceed the United States of America market average.
  • AxoGen's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:AXGN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:AXGN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 59%
NasdaqCM:AXGN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 21.1%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.6%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:AXGN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:AXGN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 246 18 13 1
2022-12-31 221 8 1 3
2021-12-31 184 -6 -9 5
2020-12-31 147 -19 -16 7
2019-12-31 112 -29 -29 7
NasdaqCM:AXGN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 90 -21 -26
2018-12-31 84 -18 -22
2018-09-30 77 -14 -20
2018-06-30 71 -13 -18
2018-03-31 65 -11 -12
2017-12-31 60 -9 -10
2017-09-30 55 -10 -14
2017-06-30 50 -10 -14
2017-03-31 45 -11 -14
2016-12-31 41 -11 -14
2016-09-30 38 -14 -12
2016-06-30 34 -14 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AxoGen's earnings are expected to grow significantly at over 20% yearly.
  • AxoGen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:AXGN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from AxoGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:AXGN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.30 0.30 0.30 1.00
2022-12-31 0.01 0.09 -0.07 2.00
2021-12-31 -0.20 -0.12 -0.31 4.00
2020-12-31 -0.40 -0.29 -0.51 4.00
2019-12-31 -0.73 -0.61 -0.88 5.00
NasdaqCM:AXGN Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.69
2018-12-31 -0.60
2018-09-30 -0.55
2018-06-30 -0.51
2018-03-31 -0.37
2017-12-31 -0.31
2017-09-30 -0.41
2017-06-30 -0.43
2017-03-31 -0.46
2016-12-31 -0.47
2016-09-30 -0.41
2016-06-30 -0.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AxoGen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AxoGen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AxoGen has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has AxoGen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AxoGen's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AxoGen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AxoGen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AxoGen's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
AxoGen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AxoGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:AXGN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 89.96 -26.26 87.90 13.85
2018-12-31 83.94 -22.40 79.74 11.77
2018-09-30 77.48 -19.67 72.09 9.94
2018-06-30 70.86 -17.69 64.61 8.43
2018-03-31 65.44 -12.32 57.73 7.35
2017-12-31 60.43 -10.45 52.37 6.70
2017-09-30 54.86 -13.57 49.29 5.91
2017-06-30 50.02 -13.75 45.62 5.23
2017-03-31 45.24 -14.50 42.32 4.64
2016-12-31 41.11 -14.41 38.56 4.21
2016-09-30 37.51 -12.40 35.59 3.93
2016-06-30 34.46 -13.07 33.74 3.74
2016-03-31 30.49 -13.46 31.02 3.54
2015-12-31 27.33 -13.36 28.51 3.24
2015-09-30 24.32 -16.24 25.92 3.33
2015-06-30 20.83 -16.50 23.09 3.07
2015-03-31 18.63 -17.05 21.37 2.89
2014-12-31 16.82 -17.71 20.14 3.03
2014-09-30 15.01 -15.33 19.14 2.68
2014-06-30 13.29 -15.64 18.23 2.59
2014-03-31 11.94 -15.36 17.09 2.53
2013-12-31 10.95 -14.56 15.97 2.13
2013-09-30 10.01 -14.49 14.84 1.87
2013-06-30 9.03 -13.17 13.94 1.67
2013-03-31 8.18 -10.75 12.74 1.54
2012-12-31 7.69 -9.42 12.10 1.43
2012-09-30 7.01 -7.51 11.24 1.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AxoGen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AxoGen has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AxoGen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AxoGen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AxoGen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is AxoGen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AxoGen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AxoGen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AxoGen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AxoGen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2110.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AxoGen Company Filings, last reported 3 months ago.

NasdaqCM:AXGN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 140.74 0.00 107.85
2018-12-31 146.98 0.00 116.61
2018-09-30 149.48 0.00 126.37
2018-06-30 150.50 0.00 133.56
2018-03-31 21.69 24.49 30.56
2017-12-31 25.18 24.55 36.51
2017-09-30 10.55 24.38 22.04
2017-06-30 11.31 24.17 23.87
2017-03-31 12.12 24.28 25.91
2016-12-31 14.92 24.31 30.01
2016-09-30 1.10 25.00 16.00
2016-06-30 2.79 24.95 18.27
2016-03-31 4.84 24.80 20.95
2015-12-31 8.20 24.70 25.91
2015-09-30 11.18 25.54 29.94
2015-06-30 -3.53 25.43 15.62
2015-03-31 -0.68 25.27 19.26
2014-12-31 -11.25 25.09 8.22
2014-09-30 -10.19 28.17 11.80
2014-06-30 -7.18 27.24 14.17
2014-03-31 -3.69 26.26 16.81
2013-12-31 0.14 25.36 20.07
2013-09-30 4.11 24.33 22.59
2013-06-30 -9.30 23.38 8.69
2013-03-31 -6.01 22.44 11.20
2012-12-31 -2.83 21.58 13.91
2012-09-30 1.21 6.63 4.45
  • AxoGen's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • AxoGen had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AxoGen has sufficient cash runway for more than 3 years based on current free cash flow.
  • AxoGen has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 20.6% each year.
X
Financial health checks
We assess AxoGen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AxoGen has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is AxoGen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AxoGen dividends.
If you bought $2,000 of AxoGen shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AxoGen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AxoGen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:AXGN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:AXGN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AxoGen has not reported any payouts.
  • Unable to verify if AxoGen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AxoGen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AxoGen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AxoGen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AxoGen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AxoGen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of AxoGen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Karen Zaderej
COMPENSATION $3,665,188
AGE 57
TENURE AS CEO 7.8 years
CEO Bio

Ms. Karen Zaderej has been the Chief Executive Officer of AxoGen, Inc. since May 2010 and also has been its President since September 30, 2011. She has been Director of Viveve Medical Inc. since September 13, 2018. She has served as the Chief Executive Officer of AxoGen Corporation and Member of AC’s Board of Directors since May 2010. Ms. Zaderej has been instrumental in the successful development and launch of AxoGen portfolio of nerve products for bridging, connecting and protecting peripheral nerves: Avance Nerve Graft, AxoGuard Nerve Connector and AxoGuard Nerve Protector. To accomplish this, she has overseen strategic Partnerships, taken AxoGen international and managed costs. Ms. Zaderej has over 20 years of experience in the medical device and tissue markets. Ms. Zaderej joined AC in May 2006 and served as its Vice President of Marketing and Sales from May 2006 to October 2007. Ms. Zaderej served as the Chief Operating Officer of AxoGen, Inc., from October 2007 to May 2010. She was a Founder of Zaderej Medical Consulting and worked for it From October 2004 to May 2006. From 1987 to 2004, Ms. Zaderej worked at Ethicon, Inc., a Johnson & Johnson company, where she held senior positions in marketing, business development and research & development, as well as ran a manufacturing business. She has been a Director of AxoGen, Inc. since September 30, 2011 and has been its Chairman since May 15, 2018. She served as a Director of LecTec Corp. since September 27, 2011. She holds an MBA from the Kellogg Graduate School of Business and a BS in Chemical Engineering from Purdue University.

CEO Compensation
  • Karen's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Karen's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the AxoGen management team in years:

1.1
Average Tenure
54.5
Average Age
  • The average tenure for the AxoGen management team is less than 2 years, this suggests a new team.
Management Team

Karen Zaderej

TITLE
Chairman
COMPENSATION
$4M
AGE
57
TENURE
7.8 yrs

Pete Mariani

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
55
TENURE
3.3 yrs

Greg Freitag

TITLE
General Counsel & Director
COMPENSATION
$857K
AGE
57
TENURE
7.8 yrs

Mike Donovan

TITLE
Vice President of Operations
AGE
54
TENURE
3.8 yrs

Kaila Krum

TITLE
Vice President of Investor Relations & Corporate Development
TENURE
1.1 yrs

John Glueck

TITLE
Chief Compliance Officer & Assistant General Counsel
TENURE
0.8 yrs

Greg Davault

TITLE
Vice President of Marketing
AGE
51
TENURE
1.1 yrs

Maria Martinez

TITLE
Chief Human Resources Officer
AGE
51
TENURE
0.8 yrs

Isabelle Billet

TITLE
Chief Strategy & Business Development Officer
AGE
57
TENURE
0.8 yrs

Eric Sandberg

TITLE
Chief Commercial Officer
AGE
54
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the AxoGen board of directors in years:

5.9
Average Tenure
58.5
Average Age
  • The tenure for the AxoGen board of directors is about average.
Board of Directors

Greg Freitag

TITLE
General Counsel & Director
COMPENSATION
$857K
AGE
57
TENURE
7.8 yrs

Mark Gold

TITLE
Director
COMPENSATION
$180K
AGE
69
TENURE
7.8 yrs

Karen Zaderej

TITLE
Chairman
COMPENSATION
$4M
AGE
57
TENURE
1.2 yrs

Robert Rudelius

TITLE
Director
COMPENSATION
$182K
AGE
63
TENURE
8.8 yrs

Guido Neels

TITLE
Director
COMPENSATION
$170K
AGE
71
TENURE
3.9 yrs

Amy Wendell

TITLE
Lead Director
COMPENSATION
$165K
AGE
58
TENURE
1.2 yrs

Bruce Mast

TITLE
Member of Board of Advisor

David Muir

TITLE
Member of Board of Advisor

James Grooms

TITLE
Director
COMPENSATION
$175K
AGE
59
TENURE
7.8 yrs

Quentin Blackford

TITLE
Director
AGE
40
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • AxoGen individual insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Jun 19 Buy Amy McBride-Wendell Individual 13. Jun 19 13. Jun 19 5,000 $20.25 $101,250
17. May 19 Sell David Hansen Individual 13. May 19 13. May 19 -20,000 $22.63 $-452,600
15. Nov 18 Sell Gregory Freitag Individual 15. Nov 18 15. Nov 18 -20,000 $32.25 $-645,000
15. Nov 18 Sell Karen Zaderej Individual 13. Nov 18 14. Nov 18 -25,000 $33.42 $-829,620
16. Aug 18 Buy Amy McBride-Wendell Individual 14. Aug 18 14. Aug 18 5,000 $36.89 $184,450
X
Management checks
We assess AxoGen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AxoGen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Have Insiders Been Selling AxoGen, Inc. (NASDAQ:AXGN) Shares?

View our latest analysis for AxoGen The Last 12 Months Of Insider Transactions At AxoGen In the last twelve months, the biggest single sale by an insider was when the Chairman, Karen Zaderej, sold US$830k worth of shares at a price of US$33.42 per share. … NasdaqCM:AXGN Recent Insider Trading, July 16th 2019 AxoGen Insiders Are Selling The Stock There was substantially more insider selling, than buying, of AxoGen shares over the last three months. … The insider sales have outweighed the insider buying, at AxoGen, in the last three months.

Simply Wall St -

Introducing AxoGen (NASDAQ:AXGN), The Stock That Soared 796% In The Last Five Years

(NASDAQ:AXGN) share price is up a whopping 796% in the last half decade, a handsome return for long term holders. … It's never too late to start following a top notch stock like AxoGen, since some long term winners go on winning for decades. … If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering.

Simply Wall St -

Is There An Opportunity With AxoGen, Inc.'s (NASDAQ:AXGN) 47% Undervaluation?

by projecting its future cash flows and then discounting them to today's value. … I will use the Discounted Cash Flow (DCF) model! … We generally believe that a company's value is the present value of all of the cash it will generate in the future.

Simply Wall St -

Are Insiders Selling AxoGen, Inc. (NASDAQ:AXGN) Stock?

So we'll take a look at whether insiders have been buying or selling shares in AxoGen, Inc. … AxoGen Insider Transactions Over The Last Year. … Over the last year we saw more insider selling of AxoGen shares, than buying

Simply Wall St -

Is AxoGen, Inc.'s (NASDAQ:AXGN) CEO Pay Fair?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Karen Zaderej's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$713m, and pays its CEO total annual compensation worth US$3.7m.

Simply Wall St -

Have Insiders Been Selling AxoGen, Inc. (NASDAQ:AXGN) Shares This Year?

So shareholders might well want to know whether insiders have been buying or selling shares in AxoGen, Inc. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … So it may not tell us anything about how insiders feel about the current share price.

Simply Wall St -

Do Directors Own AxoGen Inc (NASDAQ:AXGN) Shares?

The big shareholder groups in AxoGen Inc (NASDAQ:AXGN) have power over the company. … Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … With a market capitalization of US$1.2b, AxoGen is a decent size, so it is probably on the radar of institutional investors.

Simply Wall St -

What does AxoGen Inc's (NASDAQ:AXGN) Balance Sheet Tell Us About Its Future?

Let’s take a look at AXGN’s debt concentration and assess their financial liquidity to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … Note that this information is centred entirely on financial health and is a top-level understanding, so I encourage you to look further. … How does AXGN’s operating cash flow stack up against its debt?

Simply Wall St -

Market Sentiment Around Loss-Making AxoGen Inc (NASDAQ:AXGN)

The company’s loss has recently broadened since it announced a -US$10.45m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$12.32m, moving it further away from breakeven … Many investors are wondering the rate at which AXGN will turn a profit, with the big question being “when will the company breakeven?” … In this article, I will touch on the expectations for AXGN’s growth and when analysts expect the company to become profitable.

Simply Wall St -

At US$048.6, Is AxoGen Inc (NASDAQ:AXGN) A Buy?

AxoGen Inc (NASDAQ:AXGN), a medical equipment company based in United States,. … As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock? … However, could the stock still be trading at a relatively cheap price.

Simply Wall St -

Company Info

Description

AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Details
Name: AxoGen, Inc.
AXGN
Exchange: NasdaqCM
Founded:
$760,972,407
39,205,173
Website: http://www.axogeninc.com
Address: AxoGen, Inc.
13631 Progress Boulevard,
Suite 400,
Alachua,
Florida, 32615,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AXGN Common Stock Nasdaq Capital Market US USD 02. Oct 2011
DB LT3 Common Stock Deutsche Boerse AG DE EUR 02. Oct 2011
LSE 0HKD Common Stock London Stock Exchange GB USD 02. Oct 2011
Number of employees
Current staff
Staff numbers
288
AxoGen employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/20 00:27
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/12
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.